Mobile

A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001913-13

A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK-0524A 2g Coadministered with Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Medial Thickening (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

In patients with heterozygous familial hypercholesterolemia (HeFH): (1) To demonstrate the effects of MK-0524A coadministered with intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy compared to intensive LDL C lowering therapy alone on atherosclerosis progression as measured with non-invasive B-mode ultrasound carotid artery intima medial thickening (cIMT) measurements.

Critère d'inclusion

  • heterozygous familial hypercholesterolemia (HeFH)

Liens